The President and CEO of Almirall, Carlos Gallardo, visited ALBA with the aim of strengthening ties between the two institutions. During the visit, the Director of the ALBA Synchrotron, Caterina Biscari — accompanied by Alejandro Sánchez and Núria Valls from ALBA’s Industrial Liaison Office — showcased to Mr. Gallardo the synchrotron’s technological capabilities. ALBA is a leading scientific infrastructure equipped with advanced structural analysis and materials characterization techniques that are especially valuable for pharmaceutical research.

Almirall, one of Catalonia’s leading biopharmaceutical companies, maintains a strong commitment to innovation and pharmaceutical research. In this context, its proximity to the ALBA Synchrotron may open up new opportunities to accelerate drug development and improve R&D processes.

The meeting highlighted the potential synergies between the industrial sector and the scientific infrastructures, benefiting applied research and the competitiveness of the Catalan pharmaceutical sector.